Baidu
map

JCO:丧子之痛,如何抚慰?

2015-06-05 MedSci MedSci原创

 丧失子女的悲痛一向被视作是更强烈而持久的痛苦。考虑到这一点,丧子的父母有着更高的风险患上心理疾病。儿童癌症照护机构有机会向亲人提供持续性的照顾,但是由于员工和时间常常是有限的,所以经常出现的问题是:应该有多少资源被用于丧子后的照护以及照护的时间。研究人员描述了心理健康服务使用(MHSU)和常见的困难,从而讨论如何最好的为悲痛欲绝的父母提供安慰。 为此,科研团队进行了一次多中心

丧失子女的悲痛一向被视作是更强烈而持久的痛苦。考虑到这一点,丧子的父母有着更高的风险患上心理疾病。儿童癌症照护机构有机会向亲人提供持续性的照顾,但是由于员工和时间常常是有限的,所以经常出现的问题是:应该有多少资源被用于丧子后的照护以及照护的时间。研究人员描述了心理健康服务使用(MHSU)和常见的困难,从而讨论如何最好的为悲痛欲绝的父母提供安慰。

为此,科研团队进行了一次多中心的横断面研究。120名父母参与了此次研究,他们均是在丧子6个月到6年之间参与此次研究,他们的子女都是因为癌症去世。父母们完成自我报告的心理健康服务使用和障碍、较长时间的悲痛、抑郁、焦虑、依恋类型等的评估。41%的参与者当下使用了心理健康服务(谈话治疗、治疗精神病的药物治疗和/或一个支援团队),在他们丧子的头两年是最常见的。谈话治疗是最为常用的心理健康服务,尽管有36%的参与者最终中断了这一疗法因为这并不能起到作用。40%的参与者希望得到支持但并没有接受这一服务。最为常见的服务使用的障碍是谈论丧子之痛太过令人悲伤(这种情况占据了64%)以及很难寻找到帮助(60%)。

经历过丧子之痛的父母需要并且渴求心理健康服务。但是阻碍服务使用的障碍必须得到解决,尤其是那些使人虚弱的悲痛综合征。较高的治疗退出率表明发展更有效的悲痛干预措施极为重要。

原始出处:
Wendy G. Lichtenthal et al.Mental Health Services for Parents Who Lost a Child to
Cancer: If We Build Them, Will They Come?
.Published Ahead of Print on June 1, 2015 as 10.1200/JCO.2014.59.0406

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1891195, encodeId=a6f718911957c, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Mon Jun 15 02:05:00 CST 2015, time=2015-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26715, encodeId=81eb26e159a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:27:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26254, encodeId=a773262546b, content=悲哀呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Mon Jun 08 07:58:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26188, encodeId=387226188af, content=特别适合中国,那么多都是只有一个小孩, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13501619189, createdName=hhhhh11111, createdTime=Sat Jun 06 23:30:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26176, encodeId=5bfb261e688, content=好课题,希望做好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Jun 06 17:16:00 CST 2015, time=2015-06-06, status=1, ipAttribution=)]
    2015-06-15 lidong40
  2. [GetPortalCommentsPageByObjectIdResponse(id=1891195, encodeId=a6f718911957c, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Mon Jun 15 02:05:00 CST 2015, time=2015-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26715, encodeId=81eb26e159a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:27:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26254, encodeId=a773262546b, content=悲哀呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Mon Jun 08 07:58:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26188, encodeId=387226188af, content=特别适合中国,那么多都是只有一个小孩, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13501619189, createdName=hhhhh11111, createdTime=Sat Jun 06 23:30:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26176, encodeId=5bfb261e688, content=好课题,希望做好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Jun 06 17:16:00 CST 2015, time=2015-06-06, status=1, ipAttribution=)]
    2015-06-09 huaxipanxing

    看看

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1891195, encodeId=a6f718911957c, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Mon Jun 15 02:05:00 CST 2015, time=2015-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26715, encodeId=81eb26e159a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:27:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26254, encodeId=a773262546b, content=悲哀呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Mon Jun 08 07:58:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26188, encodeId=387226188af, content=特别适合中国,那么多都是只有一个小孩, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13501619189, createdName=hhhhh11111, createdTime=Sat Jun 06 23:30:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26176, encodeId=5bfb261e688, content=好课题,希望做好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Jun 06 17:16:00 CST 2015, time=2015-06-06, status=1, ipAttribution=)]
    2015-06-08 午夜星河

    悲哀呀

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1891195, encodeId=a6f718911957c, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Mon Jun 15 02:05:00 CST 2015, time=2015-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26715, encodeId=81eb26e159a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:27:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26254, encodeId=a773262546b, content=悲哀呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Mon Jun 08 07:58:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26188, encodeId=387226188af, content=特别适合中国,那么多都是只有一个小孩, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13501619189, createdName=hhhhh11111, createdTime=Sat Jun 06 23:30:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26176, encodeId=5bfb261e688, content=好课题,希望做好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Jun 06 17:16:00 CST 2015, time=2015-06-06, status=1, ipAttribution=)]
    2015-06-06 hhhhh11111

    特别适合中国,那么多都是只有一个小孩

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1891195, encodeId=a6f718911957c, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Mon Jun 15 02:05:00 CST 2015, time=2015-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26715, encodeId=81eb26e159a, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:27:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26254, encodeId=a773262546b, content=悲哀呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=173, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Mon Jun 08 07:58:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26188, encodeId=387226188af, content=特别适合中国,那么多都是只有一个小孩, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=13501619189, createdName=hhhhh11111, createdTime=Sat Jun 06 23:30:00 CST 2015, time=2015-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26176, encodeId=5bfb261e688, content=好课题,希望做好。, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Jun 06 17:16:00 CST 2015, time=2015-06-06, status=1, ipAttribution=)]
    2015-06-06 owlhealth

    好课题,希望做好。

    0

相关资讯

ASCO 2015:ASCO现任主席对癌症治疗下一个50年的展望

主席寄语: 就在1年前,我们共同庆祝了美国临床肿瘤学会(ASCO">ASCO)的50周年纪念日,回顾了我们已经取得的杰出成就和里程碑似的飞跃。今天,站在ASCO历史上第2个50年的起点,我们要开始思考10年、20年乃至30年后,癌症和癌症的防治会发生哪些变化。我们要如何在日渐积累的、庞大而繁杂的知识库中找到真正的“宝藏”,让癌症患者最终获益?   ——彼得·保尔·于(Peter

科学家发现癌症转移细胞学机制:扩散是转移开始

西班牙科学家马内尔·埃斯特列尔发现了肿瘤细胞从原始病灶逃离,分散到其他器官的机制,这就是肿瘤转移的开始,而转移是造成绝大多数癌症患者死亡的原因。据西班牙《先锋报》网站6月1日报道,此外科学家还发现了对现有两种药物有敏感反应的两个治疗靶点,有望使治疗变得更加有效。这一研究成果刊登在英国《自然·医学》月刊上。十分之九的癌症死者是因为肿瘤转移而死亡。这是因为与原发肿瘤不同,转移后的肿瘤往往影响到最重要的

免疫疗法治癌效果惊人 被誉40年来很大突破

英国《每日电讯报》网站6月1日报道,在一项试验中,逾半数只剩数月生命的患者体内的致命肿瘤出现萎缩甚至完全消失。近几天,研究人员在美国临床肿瘤学会芝加哥年会上宣布了大量试验性治疗的结果,这些治疗令患者的免疫系统强化,表明皮肤癌和肺部疾病的治疗前景可期。而且,昨晚该年会披露的诸多试验性治疗案例结果显示,这种疗法对多种癌症有“激动人心的”疗效。专家们说,这一进展表明,常见癌症——包括肺癌、肠癌、卵巢癌和

STM:工程改造细菌,简单检测癌症和糖尿病

斯坦福大学的研究人员最近设计并完成了一个应用在医学诊断的新工具:使用活细菌制成的生物传感器能够在感应到疾病时发出特定的颜色。研究者重新改造布阵了细菌内部的“基因电路”,使细菌能够识别尿液样品中异常的葡萄糖水平,提示糖尿病的存在。这个新技术的发明,属于合成生物学的领域的一个突破。这篇文章发表在最新一期的Science Translational Medicine。 细菌可以回应和适应它们周围的环

PLOS MED:合理膳食降低低收入人群疾病死亡率

 根据美国膳食指南(DGA)的定义,一份健康的膳食与更低的慢性疾病发病率和死亡率有所联系,这是主要在非西班牙裔白人中的研究得出的结论。但是这种联系是否可以推及到非裔美国人和低收入人群尚不得知。DGA的目标是促进健康以及预防慢性疾病,主要是向2岁以上人群通过提供循证的营养指导来实现的。健康饮食指数(HEI)也因此应运而生。更高的HEI评分就表明了膳食质量高,这与更低水平的肥胖和炎症以及更低

ASCO 2015:多个不易治愈癌症的新免疫疗法

芝加哥——今天美国临床肿瘤学会(ASCO)51届年会上公布的四个临床试验结果显示免疫疗法对多种常见固体肿瘤癌症患者是有前途的治疗策略。新的研究结果表明对于晚期肝脏、头颈部,肺部、结直肠癌症以PD-1蛋白为靶标的免疫疗法具有有效性。一些研究还发现基因标记可用于确定哪些患者从这些新疗法中受益最多。“每年靶标为免疫治疗领域的研究都会使人变得更加兴奋”FASCO,医学博士,ASCO专家 Lynn Schu

Baidu
map
Baidu
map
Baidu
map